Bio-Path Holdings, Inc.
6 clinical trials · Sponsor
◉ Watch Bio-Path Holdings, Inc.
| Record | Firm | Date |
|---|---|---|
| BP1001-A in Patients With Advanced or Recurrent Solid Tumors (NCT04196257) | Bio-Path Holdings, Inc. | 2022-08-19 |
| A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) (NCT05190471) | Bio-Path Holdings, Inc. | 2022-08-16 |
| A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (NCT04072458) | Bio-Path Holdings, Inc. | 2020-11-05 |
| Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS (NCT02923986) | Bio-Path Holdings, Inc. | 2017-09-01 |
| Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML (NCT02781883) | Bio-Path Holdings, Inc. | 2016-05-01 |
| Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS (NCT01159028) | Bio-Path Holdings, Inc. | 2010-06-01 |
Track Bio-Path Holdings, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.